CytRx just announced
substantial progress in its therapeutic agent aldoxorubicin’s phase 2 clinical
trial for treatment of unresectable glioblastoma multiforme (GBM), a lethal
variant of brain cancer. The first patient in the trial has been dosed with
aldoxorubicin in the open-label, multisite trial, which has been designed to
investigate the preliminary safety and efficacy of aldoxorubicin in patients
whose tumors have progressed following prior treatment with surgery, radiation,
and temozolomide.
“With the dosing of the
first patients we are on schedule with this important Phase 2 GBM trial, and
look forward to reporting preliminary results in the second half of this year,”
said CytRx President and CEO Steven A. Kriegsman. “Aldoxorubicin has been shown
to have the unique ability to cross the blood-brain barrier in animal models of
human glioblastoma, potentially creating a new approach to attacking brain
tumors. Should the data from this trial be positive, we will pursue the rapid
development of aldoxorubicin for unresectable GBM, including filing for
‘breakthrough therapy’ designation with the U.S. Food and Drug Administration,
which could expedite marketing approval.”
The trial is taking place at
three locations: the John Wayne Cancer Center/Sarcoma Oncology Center in Santa
Monica, the city of Hope in Duarte, California, and the Louisiana State
University Health Sciences Center in New Orleans.
According to RANO Working
Group Criteria, the purpose of the study is to determine progression-free
survival and overall survival. Its primary secondary objective is to evaluate
aldoxorubicin’s safety in the study’s participants, as exhibited by the
frequency and severity of adverse medical events. Expected to enroll up to 28 patients,
the study will have its participants randomly assigned equally to receive
either 350 mg/m2 (260 mg/m2 doxorubicin equivalent) or 250 mg/m2 (185 mg/m2
doxorubicin equivalent) of aldoxorubicin intravenously on Day 1; then this
process will be repeated daily for another 21 days until evidence of tumor
progression or abnormal toxicity become present or withdrawal consent is
posted.
In 2013, the drug was found
to be an effective treatment for swiftly progressing human brain cancer in the
brains of animals. In that preclinical trial, animals treated with
aldoxorubicin had a median survival of more than 63 days, compared with a
median survival of 25 days for animals treated with doxorubicin or saline.
Also, the lead investigator in that study found that aldoxorubicin could
potentially safely shrink glioblastoma tumors, drastically increasing medical
opportunities for a patient to survive, as the drug had remained confined to
the tumor tissue as opposed to normal brain tissue.
For more information about CytRx
and its progress with aldoxorubicin, visit: www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
